FierceBiotech

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Coho

INDIANAPOLIS and TOKYO, Aug. 15, 2011 /PRNewswire/ -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" ...
FiercePharma

Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Su

(3) Prasugrel-treated patients experienced a statistically significantly higher volume of chest tube blood loss at 12 hours post-CABG compared to the clopidogrel-treated patients (655 +/- 580 ...
Healio

Prasugrel fails to ease vaso-occlusion burden in sickle cell disease

Please provide your email address to receive an email when new articles are posted on . Treatment with prasugrel did not significantly reduce the rate of vaso-occlusive crisis in children and ...
MedPage Today

Prasugrel Strategy Rolls Short DAPT and De-Escalation Into One

In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...
Monthly Prescribing Reference

Phase 3 Trial Update of Effient for UA/NSTEMI Patients Managed Medically without Revascularization

Daiichi Sankyo and Lilly announced data from the TRILOGY ACS study, a Phase 3 trial comparing prasugrel (Effient) plus aspirin to clopidogrel (Plavix; BMS/Sanofi Pharmaceuticals Partnership) plus ...
Healio

Lessons learned from new trials of prasugrel in patients with ACS

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Efficacy is established in randomized clinical trials. Effectiveness, however, is established in ...
Medscape

Prasugrel Noninferior to Ticagrelor, but Both Achieve Poor Platelet Inhibition at Two Hours

FLORENCE, ITALY — A study comparing ticagrelor (Brilinta, AstraZeneca) and prasugrel (Effient, Lilly/Daiichi-Sanyo) in patients with ST-segment-elevation MI (STEMI) undergoing primary PCI has shown ...
Medscape

Inappropriate Prasugrel Use in One in Five PINNACLE Patients

HOUSTON, TX — Nearly one in five patients treated with prasugrel (Effient, Lilly/Daiichi Sankyo) in the PINNACLE registry is receiving the drug inappropriately or for a nonrecommended indication, ...
TCTMD

Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI ...

Indianapolis and Tokyo -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment ...